1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?

 
• By Alexandra Shimmings

Merck & Co has triumphed against the odds announcing positive top-line results from the cardiovascular outcomes trial of its CETP inhibitor anacetrapib. But questions remain about the level of benefit and the regulatory prospects.

SC1706_Falling Chairs_ 440457832_1200x675
Fallen Off Your Chair? A CETP Inhibitor Succeeds • Source: Shutterstock

Years after Pfizer Inc. dramatically discontinued the first CETP inhibitor torcetrapib – blowing a hole into a mechanism once hailed as the natural successor to the statins – Merck & Co. Inc. has breathed new life into the hypothesis by proving a cardiovascular outcomes advantage for its anacetrapib in the 30,000-patient REVEAL trial.

Merck announced June 27 that the CVOT study had met its primary endpoint, significantly reducing major coronary events (a composite of coronary death, myocardial infarction, and coronary revascularization) compared with placebo in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

More from R&D

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.